Practitioner review: bridging the gap between research and clinical practice in pediatric obesity

Elissa Jelalian1, Yana Markov Wember, Heidi Bungeroth

  • 1Department of Psychiatry, Rhode Island Hospital, Brown Medical School, Providence, RI, USA. Elissa_Jelalian@brown.edu

Insights

Pediatric obesity is a growing concern. Effective treatment for overweight children and adolescents requires individualized assessment, especially when psychiatric comorbidities are present, to tailor interventions for better outcomes.

Area of Science:

  • Pediatric Endocrinology
  • Public Health
  • Child Psychiatry

Background:

  • Pediatric obesity prevalence is increasing globally, posing significant health risks.
  • Overweight children face higher risks of medical, psychosocial, and behavioral issues.
  • This review focuses on evidence-based interventions for pediatric obesity.

Purpose of the Study:

  • To review empirical pediatric obesity treatment literature.
  • To examine diet, physical activity, and behavior interventions.
  • To address treatment considerations for overweight youth with psychiatric comorbidities.

Main Methods:

  • Conducted a review of relevant treatment literature, emphasizing randomized clinical trials.
  • Utilized prospective studies on weight status and psychological variables.
  • Incorporated findings from adult population studies for recommendations.

Main Results:

  • Established pediatric weight control interventions exist but often exclude those with psychiatric issues.
  • Individual, familial, and contextual factors specific to weight must be assessed.
  • Prioritizing treatment objectives based on individual needs is crucial.

Conclusions:

  • Current empirical and practical challenges exist in treating obese youth with psychiatric concerns.
  • Determining the appropriateness of weight control interventions for this population requires careful consideration.
  • Further research is needed to explicitly target obese children and adolescents with psychiatric conditions.
Abstract

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...